Position in VCEL
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$729,422
-$105,289 QoQ
Shares Held
22,674
-2.2% QoQ
Ownership
0.044%
of shares outstanding
% of Portfolio
0.21%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2023
7 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in VCEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026EntryPoint Capital, LLC holds $19,484,871 across 56 Biotechnology names. VCEL ranks #4 (3.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TBPH |
Theravance Biopharma, Inc.
|
49,739 | $807,263 | |
| 2 | LGND |
Ligand Pharmaceuticals Inc
|
3,922 | $783,027 | |
| 3 | ADMA |
Adma Biologics, Inc.
|
83,961 | $756,488 | |
| 4 | VCEL |
Vericel Corp
This page
|
22,674 | $729,422 | |
| 5 | HRMY |
Harmony Biosciences Holdings, Inc.
|
24,264 | $679,634 | |
| 6 | UPB |
Upstream Bio, Inc.
|
73,568 | $662,112 | |
| 7 | INCY |
Incyte Corp
|
6,483 | $610,179 | |
| 8 | RARE |
Ultragenyx Pharmaceutical Inc.
|
26,119 | $547,193 |
All Filings in VCEL
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $729,422 | 22,674 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $834,711 | 23,180 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $264,757 | 8,413 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $449,285 | 10,559 | Shares | Sole | 2025-08-11 | |
| 2024-06-30 | $141,081 | 3,075 | Shares | Sole | 2024-08-13 | |
| 2024-03-31 | $96,132 | 1,848 | Shares | Sole | 2024-05-14 | |
| 2023-12-31 | $243,145 | 6,828 | Shares | Sole | 2024-02-14 | |
| No filing history on record for this holder in this stock. | ||||||